SCHEMBL6407775

SCHEMBL6407775

O=C(N[C@H](CO)Cc1c[nH]c2ccccc12)C1(c2ccc(Cl)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 8/20 0.52
DRD3 P35462 8/20 0.52
DRD2 P14416 7/20 0.52
UGCG Q16739 2/20 0.50
CYP3A4 P08684 2/20 0.50
TACR1 P25103 1/20 0.48
MEN1 O00255 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
KMT2A Q03164 2/20 0.47
LMNA P02545 1/20 0.47
CYP1A2 P05177 1/20 0.47
HTR1A P08908 1/20 0.47
CHRM5 P08912 1/20 0.47
ADRA2A P08913 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
TSHR P16473 1/20 0.47
ADRA2B P18089 1/20 0.47
DRD1 P21728 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4963772 0.79 TRPA1 (0.53) CYP3A4CYP2D6CYP2C9HDAC4
SCHEMBL21326311 0.79 UGCG (0.79) DRD4DRD3DRD2UGCGCYP3A4
SCHEMBL21326314 0.79 UGCG (0.79) DRD4DRD3DRD2UGCGCYP3A4
SCHEMBL6405987 0.79 AVPR1A (0.53) LMNAHDAC4
SCHEMBL4965651 0.76 ECE1 (0.47) MEN1KMT2ALMNATSHRRECQL
SCHEMBL3139850 0.76 ACE (0.50) TACR1MEN1NPC1RAB9AKMT2A
SCHEMBL19412126 0.76 SMN1; SMN2 (0.59) MEN1KMT2ALMNATSHRRECQL
SCHEMBL19412127 0.76 SMN1; SMN2 (0.59) MEN1KMT2ALMNATSHRRECQL
SCHEMBL1177219 0.76 ECE1 (0.59) MEN1NPC1RAB9AKMT2ALMNA
SCHEMBL1177195 0.76 ECE1 (0.59) MEN1NPC1RAB9AKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050288338-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-29 US claimed
US-20050288338-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288338-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 DRD4 3106/4885DRD3 1614/4885DRD2 2127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.